Thomas Mehrling

434 total citations
22 papers, 258 citations indexed

About

Thomas Mehrling is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, Thomas Mehrling has authored 22 papers receiving a total of 258 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 7 papers in Genetics and 6 papers in Oncology. Recurrent topics in Thomas Mehrling's work include Histone Deacetylase Inhibitors Research (10 papers), Protein Degradation and Inhibitors (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Thomas Mehrling is often cited by papers focused on Histone Deacetylase Inhibitors Research (10 papers), Protein Degradation and Inhibitors (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Thomas Mehrling collaborates with scholars based in United Kingdom, United States and Spain. Thomas Mehrling's co-authors include Yi Chen, D A Soltis, Vincenzo Tombolini, Antonella Vetuschi, Simona Pompili, Alessandro Colapietro, Claudio Festuccia, Neus Villamor, Francesco Marampon and Dolors Colomer and has published in prestigious journals such as Blood, Cancer Research and Kidney International.

In The Last Decade

Thomas Mehrling

22 papers receiving 256 citations

Peers

Countries citing papers authored by Thomas Mehrling

Since Specialization

Citations

This map shows the geographic impact of Thomas Mehrling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Mehrling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Mehrling more than expected).

Fields of papers citing papers by Thomas Mehrling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Mehrling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Mehrling. The network helps show where Thomas Mehrling may publish in the future.

Co-authorship network of co-authors of Thomas Mehrling

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Mehrling. A scholar is included among the top collaborators of Thomas Mehrling based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Mehrling. Thomas Mehrling is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A FIRST‐IN‐HUMAN TRIAL OF THE NOVEL MULTI‐ACTION THERAPY TINOSTAMUSTINE (EDO‐S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) 2019 ·Hematological Oncology ·(unknown), Rosaria De Filippi, Pier Luigi Zinzani, Christoph Driessen, Han W. Tun, (unknown), (unknown), Thomas Mehrling, Owen A. O’Connor	1
2	Abstract CT023: Dose escalation of tinostamustine in patients with advanced solid tumors 2019 ·Cancer Research ·Alain C. Mita, Markus Loeffler, Nam Q. Bui, Thomas Mehrling, (unknown), Ronald B. Natale, Shivaani Kummar	2
3	PF300 DOSE ESCALATION OF TINOSTAMUSTINE IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LYMPHOID MALIGNANCIES 2019 ·HemaSphere ·(unknown), António E. Pinto, Rosaria De Filippi, Christoph Driessen, Han W. Tun, (unknown), (unknown), Thomas Mehrling, Owen A. O’Connor	1
4	Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized phase II study 2019 ·Annals of Oncology ·Ulrich F. Pape, Stefan Kasper, (unknown), M. Sinn, Arndt Vogel, Lothar Mueller, Oswald Burkhard, K Caca, Steffen Heeg, (unknown), Anja A. Kühl, Ruža Arsenić, Hendrik Jansen, Thomas Mehrling, (unknown), Ina Wagner, Nalân Utku	1
5	Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis 2018 ·Kidney International ·Dearbhaile Dooley, Mirjan M. van Timmeren, Vincent O’Reilly, Gareth Brady, Eóin C. O’Brien, (unknown), Fionnuala B. Hickey, (unknown), Charles D. Pusey, Frederick W.K. Tam, Thomas Mehrling, Peter Heeringa, Mark A. Little	3
6	The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma 2018 ·Journal of Hematology & Oncology ·Claudio Festuccia, Andrea Mancini, Alessandro Colapietro, Giovanni Luca Gravina, Flora Vitale, Francesco Marampon, Simona Delle Monache, Simona Pompili, Loredana Cristiano, Antonella Vetuschi, Vincenzo Tombolini, Yi Chen, Thomas Mehrling	48
7	Strategy for Assessing New Drug Value in Orphan Diseases: An International Case Match Control Analysis of the PROPEL Study 2018 ·JNCI Cancer Spectrum ·Owen A. O’Connor, Enrica Marchi, Weining Volinn, Jin Shi, Thomas Mehrling, Won Seog Kim	14
8	Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy 2018 ·Antibodies ·Thomas Mehrling, D A Soltis	13
9	Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models 2018 ·Oncotarget ·(unknown), Zhimin Li, John A. Copland, Thomas Mehrling, Han W. Tun	5
10	Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair 2017 ·Journal of Hematology & Oncology ·(unknown), Ana B. Herrero, Marta Chesi, Laura San‐Segundo, (unknown), Susana Hernández-García, Irena Misiewicz-Krzemińska, Dalia Quwaider, (unknown), (unknown), Teresa Paíno, P. Leif Bergsagel, Thomas Mehrling, Marcos González, Jesús F. San Miguel, María‐Victoria Mateos, Norma C. Gutiérrez, Mercedes Garayoa, Enrique M. Ocio	31
11	The First in Class, Alkylator-Histone-Deacetylase-Inhibitor Fusion Molecule Edo-S101 in Combination with Proteasome Inhibitors Induces Highly Synergistic Pro-Apoptotic Signaling through UPR Activation and Suppression of c-Myc and BCL2 in Multiple Myeloma 2016 ·Blood ·Lenka Bešše, Marianne Kraus, Andrej Bešše, (unknown), Thomas Mehrling, Christoph Driessen	2
12	The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101 2015 ·Anti-Cancer Agents in Medicinal Chemistry ·Thomas Mehrling, Yi Chen	25
13	The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone 2015 ·Blood ·(unknown), Ana B. Herrero, Laura San‐Segundo, Susana Hernández-García, (unknown), (unknown), (unknown), Teresa Paíno, Mercedes Garayoa, Thomas Mehrling, Norma C. Gutiérrez, Jesús F. San Miguel, María‐Victoria Mateos, Enrique M. Ocio	1
14	The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones 2015 ·Blood ·Rosaria De Filippi, Stefania Crisci, (unknown), (unknown), (unknown), Domenico Galati, Serena Zanotta, Gaetana Capobianco, Francesco Volzone, Manuela Arcamone, Piera Maiolino, (unknown), Gaetano Corazzelli, Ferdinando Frigeri, Thomas Mehrling, Antonio Pinto	2
15	Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma 2014 ·Haematologica ·(unknown), Jacoline E. C. Bromberg, Maryalice Stetler‐Stevenson, Seth M. Steinberg, Lourdes Martín‐Martín, (unknown), Juan‐Manuel Sancho, (unknown), (unknown), Rik A. Brooimans, Blanca Sánchez‐González, Antonio Salar, Eva González‐Barca, Josep‐María Ribera, Margaret Shovlin, Armando Filie, Kieron Dunleavy, Thomas Mehrling, Michele Spina, (unknown)	52
16	The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies 2014 ·Blood ·(unknown), Laura San‐Segundo, (unknown), Susana Hernández-García, (unknown), Mercedes Garayoa, (unknown), Teresa Paíno, María‐Victoria Mateos, Yi Chen, Enrique M. Ocio, Thomas Mehrling	4
17	Edo- S101, a New Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Has Superior Activity Against Myeloma and B Cell Lymphoma and Strong Synergy with Proteasome Inhibitors in Vitro 2014 ·Blood ·Marianne Kraus, Jürgen Bader, Thomas Mehrling, Christoph Driessen	2
18	Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM 2009 ·Blood ·(unknown), Mònica López‐Guerra, Ramanda Upshaw, Shanta Bantia, Caroline Smal, Françoise Bontemps, (unknown), Thomas Mehrling, Neus Villamor, Elı́as Campo, Emili Montserrat, Dolors Colomer	41
19	The purine nucleoside phosphorylase inhibitor forodesine induces p53-independent apoptosis in chronic lymphocytic leukemia through caspase-8 activation, Mcl-1 downregulation, conformational changes of Bax and Bak and ROS generation. 2007 ·Molecular Cancer Therapeutics ·Roberto Alonso, Neus Villamor, Ramanda Upshaw, Shanta Bantia, Thomas Mehrling, Elı́as Campo, Emili Montserrat, Dolors Colomer	2
20	The Purine Nucleoside Phosphorylase Inhibitor Forodesine (BCX-1777) Is a Potent Cytotoxic Agent and Has Synergistic Activity with Bendamustine in Chronic Lymphocytic Leukemia (CLL) Irrespective of ZAP-70 Levels and p53 Status. 2007 ·Blood ·Roberto Alonso, Neus Villamor, Ramanda Upshaw, Shanta Bantia, Thomas Mehrling, Elı́as Campo, Emili Montserrat, Dolors Colomer	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact